THOUSAND OAKS, Calif.,
July 23, 2020 /PRNewswire/
-- Amgen (NASDAQ:AMGN) today announced that its Board of
Directors declared a $1.60 per share
dividend for the third quarter of 2020. The dividend will be paid
on September 8, 2020, to all
stockholders of record as of the close of business on August 17, 2020.
About Amgen
Amgen is committed to
unlocking the potential of biology for patients suffering from
serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by
using tools like advanced human genetics to unravel the
complexities of disease and understand the fundamentals of human
biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has
reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
Amgen Forward-Looking Statements
This news release
contains forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including any statements on the
outcome, benefits and synergies of
collaborations, or potential
collaborations, with any other
company, including Adaptive Biotechnologies
(including statements regarding such
collaboration's ability to discover and
develop fully-human neutralizing antibodies targeting SARS-CoV-2 to
potentially prevent or treat COVID-19), BeiGene, Ltd., or the
Otezla® (apremilast) acquisition, including anticipated Otezla
sales growth and the timing of non-GAAP
EPS accretion, as well as estimates
of revenues, operating margins, capital
expenditures, cash, other financial
metrics, expected legal, arbitration,
political, regulatory or clinical results
or practices, customer and prescriber
patterns or practices, reimbursement
activities and outcomes, effects of
pandemicsor other widespread health
problems such as the ongoing COVID-19
pandemic on our business, outcomes,
progress, or effects relating to
studies of Otezla as a potential
treatment for COVID-19, and other
such estimates and results. Forward-looking
statements involve significant risks and
uncertainties, including those discussed
below and more fully described
in the Securities and Exchange Commission reports filed by
Amgen, including our most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and current reports on
Form 8-K. Unless otherwise noted, Amgen is providing this
information as of the date of this news release and
does not undertake any obligation
to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be
guaranteed and actual results may differ
materially from those we project. Our results may
be affected by our ability to successfully market both new and
existing products domestically and
internationally, clinical and regulatory
developments involving current and future
products, sales growth of
recently launched products,
competition from other
products including biosimilars,
difficulties or delays in
manufacturing our products and global
economic conditions. In addition, sales of
our products are affected by
pricing pressure, political and public
scrutiny and reimbursement policies imposed
by third-party payers, including
governments, private insurance plans and managed
care providers and may be affected by regulatory, clinical and
guideline developments and domestic and
international trends toward managed
care and healthcare cost containment.
Furthermore, our research, testing,
pricing, marketing and other
operations are subject to extensive
regulation by domestic and foreign government regulatory
authorities. We or others could identify safety, side effects or
manufacturing problems with our
products, including our devices, after
they are on the market. Our business may be
impacted by government investigations, litigation and product
liability claims. In addition, our business may
be impacted by the adoption of
new tax legislation or exposure
to additional tax liabilities. If we
fail to meet the compliance
obligations in the corporate
integrity agreement between us and
the U.S. government, we could
become subject to significant
sanctions. Further, while we routinely obtain
patents for our products and
technology, the protection offered by
our patents and patent applications may be
challenged, invalidated or circumvented by our competitors, or we
may fail to prevail in present and future
intellectual property litigation. We perform a
substantial amount of our commercial
manufacturing activities at a few key facilities, including in
Puerto Rico, and also depend on
third parties for a portion of our
manufacturing activities, and limits
on supply may constrain sales
of certain of our current products
and product candidate development. An
outbreak of disease or similar
public health threat, such as COVID-19, and the public and
governmental effort to mitigate against the spread of such
disease, could have a significant adverse
effect on the supply of
materials for our manufacturing activities,
the distribution of our products,
the commercialization of our product
candidates, and our clinical trial
operations, and any such events
may have a material adverse effect
on our product development, product
sales, business and results of
operations. We rely on collaborations
with third parties for the development of some of our product
candidates and for the commercialization and sales of some of our
commercial products. In addition, we compete with other companies
with respect to many of our marketed products
as well as for the discovery
and development of new products.
Discovery or identification of new
product candidates or development of
new indications for existing products
cannot be guaranteed and movement
from concept to product is
uncertain; consequently, there can be
no guarantee that any particular
product candidate or development of a new
indication for an existing product will be
successful and become a commercial
product. Further, some raw materials,
medical devices and component parts
for our products are supplied
by sole third-party suppliers. Certain
of our distributors, customers and
payers have substantial purchasing
leverage in their dealings with us.
The discovery of significant problems
with a product similar to one
of our products that implicate an entire
class of products could have a
material adverse effect on sales
of the affected products and on our
business and results of operations. Our efforts to collaborate with
or acquire other companies, products or technology, and
to integrate the operations of
companies or to support the products
or technology we have acquired, may not
be successful. A breakdown, cyberattack or
information security breach could compromise
the confidentiality, integrity and
availability of our systems and
our data. Our stock price is volatile
and may be affected by a
number of events. Our business
performance could affect or limit the
ability of our Board of Directors
to declare a dividend or our
ability to pay a dividend or
repurchase our common stock. We may not be able to access the
capital and credit markets on terms that are favorable to us, or at
all.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Trish Rowland,
805-447-5631(media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-announces-2020-third-quarter-dividend-301099038.html
SOURCE Amgen